Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma

NCT02482454 is registered in ClinicalTrials.gov with The First People's Hospital of Changzhou as lead sponsor.

NCT NCT02482454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02482454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma
Lead sponsor
The First People's Hospital of Changzhou
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
July 31, 2012
Completion date
July 31, 2033
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma